Zein - laponite coacervate aided co-delivery of curcumin and cisplatin towards MDA-MB-231 breast cancer cells: Validating the concept

IF 4.6 Q1 CHEMISTRY, APPLIED
Preeti Tiwari , Masood Nadeem , Sara Dua , M.MoshahidA. Rizvi , Najmul Arfin
{"title":"Zein - laponite coacervate aided co-delivery of curcumin and cisplatin towards MDA-MB-231 breast cancer cells: Validating the concept","authors":"Preeti Tiwari ,&nbsp;Masood Nadeem ,&nbsp;Sara Dua ,&nbsp;M.MoshahidA. Rizvi ,&nbsp;Najmul Arfin","doi":"10.1016/j.fhfh.2023.100164","DOIUrl":null,"url":null,"abstract":"<div><p>Cancer cell resistance towards drugs leads to limited drug efficacy and therefore, combination therapy of drugs has emerged as a solution. In addition to this, the importance of a carrier system for the co-delivery of drugs to improve the potential of anti-cancer drug efficacy cannot be overlooked. Nowadays, polymer-rich dense phases of liquid droplets, known as coacervates, have emerged as an appealing option to be utilised as drug carriers. Our previous study which reported the complexation between zein and laponite to form coacervates and their future prospect as dual drug carriers has been extended in this work. The present work has validated the usefulness of the synthesized coacervate as a dual-drug carrier for a hydrophilic drug (cisplatin) and a hydrophobic drug (curcumin) towards a breast cancer cell line (MDA-MB-231). The MTT assay and flow cytometry data for MDA-MB-231 cells suggested that the coacervate carrying dual drugs effectively transported anticancer drugs to the cancer cells, thereby arresting their cell cycle in the S phase (by neutral coacervates, X<sub>1</sub>) and in the G<sub>2</sub>/M phase (by charged coacervates, X<sub>2</sub>). Further, it is also revealed that the amount of cisplatin needed to achieve half maximal inhibitory concentration (IC<sub>50</sub>) was reduced by a maximum of 70% when flavonoid (curcumin) was used in combination with cisplatin due to synergistic effect.</p></div>","PeriodicalId":12385,"journal":{"name":"Food Hydrocolloids for Health","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Food Hydrocolloids for Health","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667025923000481","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer cell resistance towards drugs leads to limited drug efficacy and therefore, combination therapy of drugs has emerged as a solution. In addition to this, the importance of a carrier system for the co-delivery of drugs to improve the potential of anti-cancer drug efficacy cannot be overlooked. Nowadays, polymer-rich dense phases of liquid droplets, known as coacervates, have emerged as an appealing option to be utilised as drug carriers. Our previous study which reported the complexation between zein and laponite to form coacervates and their future prospect as dual drug carriers has been extended in this work. The present work has validated the usefulness of the synthesized coacervate as a dual-drug carrier for a hydrophilic drug (cisplatin) and a hydrophobic drug (curcumin) towards a breast cancer cell line (MDA-MB-231). The MTT assay and flow cytometry data for MDA-MB-231 cells suggested that the coacervate carrying dual drugs effectively transported anticancer drugs to the cancer cells, thereby arresting their cell cycle in the S phase (by neutral coacervates, X1) and in the G2/M phase (by charged coacervates, X2). Further, it is also revealed that the amount of cisplatin needed to achieve half maximal inhibitory concentration (IC50) was reduced by a maximum of 70% when flavonoid (curcumin) was used in combination with cisplatin due to synergistic effect.

玉米蛋白-拉脱石凝聚体辅助姜黄素和顺铂对MDA-MB-231乳腺癌细胞的共递送:验证概念
癌症细胞对药物的耐药性导致药物疗效有限,因此,药物联合治疗已成为一种解决方案。除此之外,载体系统对于共同递送药物以提高抗癌药物疗效的潜力的重要性也不容忽视。如今,液滴中富含聚合物的致密相(称为凝聚层)已成为用作药物载体的一种有吸引力的选择。我们之前的研究报道了玉米醇溶蛋白和褐铁矿之间络合形成凝聚层,以及它们作为双药物载体的未来前景,这项工作得到了扩展。本工作已经验证了合成的凝聚层作为亲水性药物(顺铂)和疏水性药物(姜黄素)的双重药物载体对乳腺癌症细胞系(MDA-MB-231)的有效性。MDA-MB-231细胞的MTT测定和流式细胞术数据表明,携带双重药物的凝聚层有效地将抗癌药物转运到癌症细胞,从而在S期(通过中性凝聚层,X1)和G2/M期(通过带电凝聚层,X2)阻止其细胞周期。此外,还揭示了当类黄酮(姜黄素)与顺铂联合使用时,由于协同作用,达到一半最大抑制浓度(IC50)所需的顺铂的量最多减少了70%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.50
自引率
0.00%
发文量
0
审稿时长
61 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信